EXHIBIT 99.1

  SIMULATIONS PLUS ANNOUNCES RECORD REVENUES FOR FOURTH QUARTER AND FISCAL YEAR

              COMPANY EXPECTS TO APPLY FOR NASDAQ SMALLCAP LISTING

LANCASTER, CA, AUGUST 29, 2003. Simulations Plus, Inc. (OTCBB: SIMU.OB), the
leading provider of ADME absorption simulation and neural net
structure-to-property prediction software for pharmaceutical discovery and
development, today reported preliminary revenue for the fiscal fourth quarter
and fiscal year ended August 31, 2003.

Ronald Creeley, vice president of Marketing and Sales for Simulations Plus,
said, "I'm pleased and excited to report that a major pharmaceutical company
recently signed a multi-year subscription to a modified ADME Partners program.
ADME Partners is a software licensing program developed by Simulations Plus to
provide clients cost-effective, multiple-location site licenses with unlimited
access to all Simulations Plus software programs. The result of this sale along
with our other sales for the fourth quarter is that fourth quarter
pharmaceutical software and services revenues will approach $1.5 million, more
than doubling the previous high quarter record set last quarter. The modified
subscription does not include the usual consultation and training, but covers
only software licenses."

Momoko Beran, chief financial officer of Simulations Plus, said, "Our
preliminary numbers show pharmaceutical software and services revenues increased
148.7% to $1,480,000 for the fourth quarter compared to $595,000 for the fourth
fiscal quarter of 2002, and for the fiscal year increased 55.8% to $3,183,000,
compared to $2,043,000 for fiscal 2002. Total revenues including our Words+
subsidiary increased 72.6% to a new record $2,089,000 for the fourth quarter
compared to $1,210,000 for the fourth fiscal quarter of 2002. Fourth quarter
revenues for our Words+ subsidiary decreased 1.0% over last year's fourth
quarter. For the fiscal year, Words+ revenues decreased 1.5%. Total revenues for
the fiscal year, including the Words+ subsidiary, increased 24.8% to $5,547,000,
compared to $4,444,000 for fiscal 2002."

Ms. Beran continued, "Based on the information we have right now, we expect
fourth quarter fully diluted earnings to be between $0.17 and $0.21 per share,
and for the fiscal year, between $0.28 and $0.32 per share."

Walt Woltosz, chairman and chief executive officer of Simulations Plus,
commented, "It's difficult to contain our excitement about this year's
performance. We've maintained steady growth, growing profitability, and made
significant expansions to our product line this year. It is our current
understanding that our earnings for this fiscal year will enable us to apply for
listing on Nasdaq SmallCap, provided that the stock price exceeds $4.00. This
will probably have to wait until our 10K is filed in November."

Woltosz continued, "Simulations Plus enjoys a reputation for excellence in
science and software. Our consulting expertise and software products have served
many of the top scientists in some of the largest research organizations in the
world. However, we will not rest on our laurels. We intend to leverage our
technical and financial strengths to fuel further growth by identifying and
fulfilling needs in pharmaceutical research as we have done with GastroPlus(TM),
QMPRPlus(TM), and QMPRchitect(TM)."

ABOUT SIMULATIONS PLUS, INC.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery
and development simulation software, which is licensed to and used in the
conduct of drug research by major pharmaceutical and biotechnology companies
worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM),
which are based on its proprietary software technologies. Simulations Plus,
Inc., is headquartered in Southern California and trades on the OTCBB under the
symbol "SIMU.OB." For more information, visit our Web site at
www.simulations-plus.com.
-------------------------



Safe Harbor Statement Under the Private Securities Litigation Act 1995 - With
the exception of historical information, the matters discussed in this press
release are forward-looking statements that involve a number of risks and
uncertainties. The actual future results of the Company could differ
significantly from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: the ability of the Company to
book revenues and earnings as it expects for the current quarter, the ability of
the Company to maintain its competitive advantage, the general economics of the
pharmaceutical industry, the ability of the Company to attract and maintain
sufficient scientific and technical staff to sustain its R&D and customer
support functions, and a sustainable market. Further information on the
Company's risk factors is contained in the Company's quarterly and annual
reports as filed with the Securities and Exchange Commission.

                                       ###